Probenecid and Colchicine NDC 50742-263

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-263Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0263Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-263-01	50742026301	100 TABLET in 1 BOTTLE (50742-263-01)Marketed from May 16, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Probenecid and Colchicine
Generic name (nonproprietary): probenecid and colchicine
Active ingredients: Probenecid — 500 mg/1Colchicine — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Ingenus Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040618
Marketing start: May 16, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Alkaloids (Chemical structure)
Identifiers: Product ID 50742-263_8f0d4438-1ba8-419c-864f-b95cb0b006efSPL ID 8f0d4438-1ba8-419c-864f-b95cb0b006efSPL set ID b85d3e27-70ff-4533-b463-410e4fb23813RxCUI 198153UNII PO572Z7917, SML2Y3J35TUPC 0350742263011
Pharmacologic class: Alkaloid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742026301 followed by a unit qualifier and the quantity

Package 50742-0263-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 13, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)